The World Health Organisation has identified several experimental treatments and vaccines for Bundibugyo virus disease as promising enough to move into clinical trials, marking the first coordinated push to develop approved medicines for the virus.
Currently, no licensed drugs or vaccines exist specifically to prevent or treat BVD, the rare Ebola variant first discovered in Uganda in 2007. The WHO statement said candidate products have shown enough potential in laboratory and early testing to warrant human trials, a crucial step before any drug can reach patients.
Bundibugyo virus belongs to the Ebola family but has a lower mortality rate than other strains, typically killing about 25 to 35 percent of infected people compared to the 90 percent fatality rate of the Zaire strain that devastated West Africa in 2014 and 2015. Despite this, it remains deadly and periodic outbreaks continue in central Africa, with Uganda recording multiple cases in recent years.
The decision to prioritise BVD treatments reflects growing international concern about rare viral threats and the need for medical countermeasures before outbreaks become widespread. The WHO did not name the specific candidate products or give timelines for when trials would begin, but the move signals that the organisation and its partners believe developing these tools is scientifically feasible.
Outbreaks of Bundibugyo virus have been limited in scale compared to other Ebola variants, but healthcare workers and communities in affected regions remain vulnerable. The lack of approved treatments means doctors can only offer supportive care—fluids, oxygen, management of complications—while patients' immune systems fight the infection.
The WHO said it would work with manufacturers, research institutions, and member states to move the candidate products through clinical development stages. The next phase will involve testing safety and efficacy in human volunteers, a process that typically takes years even under accelerated conditions.
No announcement has been made about funding for these trials or which countries will host the clinical studies, though previous Ebola vaccine trials took place in Guinea, Liberia, and Sierra Leone.
